Phase 3 Trial: 225-Ac-PSMA-617 + ARPI vs SOC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxFG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxThe Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxENV105 to Reverse Resistance to ADT and ARSI
/1 Comment/in Clinical Trial, Metastatic, Phase 2/by MaxUpdate: 67Cu-SAR-bisPSMA for mCRPC Has Been Fast-Tracked by FDA
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxASCO GU 2025: Combination Therapy with Cabozantinib and Atezolizumab Shows Promise for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTransdermal Estradiol Patches Show Promise as a Safer Alternative to Traditional Hormone Therapy in Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab July 30, 2025
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025